LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Acute promyelocytic leukemia with

    Santana-Hernández, Jennifer / Corona-Rivera, Alfredo / Mendoza-Maldonado, Lucero / Santana-Bejarano, Uriel Francisco / Cuero-Quezada, Idalid / Marquez-Mora, Aurea / Serafín-Saucedo, Graciela / Brukman-Jiménez, Sinhue Alejandro / Corona-Rivera, Román / Ortuño-Sahagún, Daniel / Cruz-Osorio, Rosa Margarita / Sánchez-Zubieta, Fernando Antonio / Bobadilla-Morales, Lucina

    Oncology letters

    2024  Volume 27, Issue 3, Page(s) 114

    Abstract: Patients with acute promyelocytic leukemia (APL) exhibit the t(15;17)(q24.1;q21.2) translocation that produces the promyelocytic leukemia ( ...

    Abstract Patients with acute promyelocytic leukemia (APL) exhibit the t(15;17)(q24.1;q21.2) translocation that produces the promyelocytic leukemia (
    Language English
    Publishing date 2024-01-22
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 2573196-8
    ISSN 1792-1082 ; 1792-1074
    ISSN (online) 1792-1082
    ISSN 1792-1074
    DOI 10.3892/ol.2024.14246
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Prospective multicenter evaluation of real time PCR Kit prototype for early diagnosis of congenital Chagas disease.

    Benatar, Alejandro Francisco / Danesi, Emmaría / Besuschio, Susana Alicia / Bortolotti, Santiago / Cafferata, María Luisa / Ramirez, Juan Carlos / Albizu, Constanza Lopez / Scollo, Karenina / Baleani, María / Lara, Laura / Agolti, Gustavo / Seu, Sandra / Adamo, Elsa / Lucero, Raúl Horacio / Irazu, Lucía / Rodriguez, Marcelo / Poeylaut-Palena, Andrés / Longhi, Silvia Andrea / Esteva, Mónica /
    Althabe, Fernando / Rojkin, Federico / Bua, Jacqueline / Sosa-Estani, Sergio / Schijman, Alejandro Gabriel

    EBioMedicine

    2021  Volume 69, Page(s) 103450

    Abstract: Background: Current algorithm for Congenital Chagas Disease (cCD) diagnosis is unsatisfactory due to low sensitivity of the parasitological methods. Moreover, loss to follow-up precludes final serodiagnosis after nine months of life in many cases. A ... ...

    Abstract Background: Current algorithm for Congenital Chagas Disease (cCD) diagnosis is unsatisfactory due to low sensitivity of the parasitological methods. Moreover, loss to follow-up precludes final serodiagnosis after nine months of life in many cases. A duplex TaqMan qPCR kit for Trypanosoma cruzi DNA amplification was prospectively evaluated in umbilical cord (UCB) and peripheral venous blood (PVB) of infants born to CD mothers at endemic and non-endemic sites of Argentina.
    Methods: We enrolled and followed-up 370 infants; qPCR was compared to gold-standard cCD diagnosis following studies of diagnostic accuracy guidelines.
    Findings: Fourteen infants (3·78%) had cCD. The qPCR sensitivity and specificity were higher in PVB (72·73%, 99·15% respectively) than in UCB (66·67%, 96·3%). Positive and negative predictive values were 80 and 98·73% and 50 and 98·11% for PVB and UCB, respectively. The Areas under the Curve (AUC) of ROC analysis for qPCR and micromethod (MM) were 0·81 and 0·67 in UCB and 0·86 and 0·68 in PVB, respectively. Parasitic loads ranged from 37·5 to 23,709 parasite equivalents/mL. Discrete typing Unit Tc V was identified in five cCD patients and in six other cCD cases no distinction among Tc II, Tc V or Tc VI was achieved.
    Interpretation: This first prospective field study demonstrated that qPCR was more sensitive than MM for early cCD detection and more accurate in PVB than in UCB. Its use, as an auxiliary diagnostic tool to MM will provide more accurate records on cCD incidence.
    Funding: FITS SALUD 001-CHAGAS (FONARSEC, MINCyT, Argentina) to the Public-Private Consortium (INGEBI-CONICET, INP-ANLIS MALBRAN and Wiener Laboratories); ERANET-LAC-HD 328 to AGS and PICT 2015-0074 (FONCYT, MinCyT) to AGS and FA.
    MeSH term(s) Adult ; Chagas Disease/congenital ; Chagas Disease/diagnosis ; Early Diagnosis ; Female ; Humans ; Infant, Newborn ; Male ; Reagent Kits, Diagnostic/standards ; Real-Time Polymerase Chain Reaction/methods ; Real-Time Polymerase Chain Reaction/standards ; Sensitivity and Specificity
    Chemical Substances Reagent Kits, Diagnostic
    Language English
    Publishing date 2021-06-26
    Publishing country Netherlands
    Document type Evaluation Study ; Journal Article ; Multicenter Study
    ZDB-ID 2851331-9
    ISSN 2352-3964
    ISSN (online) 2352-3964
    DOI 10.1016/j.ebiom.2021.103450
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: In vitro

    Santana-Bejarano, Uriel Francisco / Bobadilla-Morales, Lucina / Mendoza-Maldonado, Lucero / Torres-Anguiano, Elizabeth / Brukman-Jiménez, Sinhue Alejandro / Barba-Barba, Cesar Cenobio / Corona-Rivera, Jorge Román / Corona-Rivera, Alfredo

    Oncology letters

    2019  Volume 17, Issue 6, Page(s) 5224–5240

    Abstract: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), is characterized by the t(9;22)(q34q11) that generates the BCR-ABL protein with uncontrolled tyrosine kinase activity. Recently, a connection between BCR-ABL signaling with NF-κB ... ...

    Abstract Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), is characterized by the t(9;22)(q34q11) that generates the BCR-ABL protein with uncontrolled tyrosine kinase activity. Recently, a connection between BCR-ABL signaling with NF-κB activation mediated by CK2 has been hypothesized. Approximately 95% of patients with Ph+ ALL have the BCR-ABLp190 isoform, which causes aggressive leukemia with a high rate of chemotherapy resistance. Therefore, the use of compounds that could improve the efficacy of chemotherapy drugs is of particular interest. Curcumin is an active chemical in turmeric with antineoplastic potential; it regulates protein-kinases by modulating downstream molecular pathways. The present study evaluated the effect of curcumin in combination with the chemotherapeutic drugs vincristine, imatinib and daunorubicin in the human OP-1 cell line. Several doses of the chemotherapy drugs were examined, and the effects were evaluated following 12, 24 and 48 h of exposure. The interaction between the chemotherapy drugs and curcumin was determined by the dose-effect curve, which generated a combination index (CI); these data were represented in isobolograms. In addition, the individual effect of each drug was compared with its effect in combination with curcumin on cell viability, apoptosis degree, NF-κB activation and gene expression changes. The present study observed that curcumin potentiates the efficacy of vincristine and imatinib, generating an additive/synergistic effect in a dose- and time-dependent manner. These combinations significantly increased the apoptosis degree, decreased the activation of NF-κB and the expression of its regulated genes. Conversely treatment with daunorubicin + curcumin combination produced an antagonistic/additive effect in a dose-dependent manner, and this combination significantly increased the apoptosis degree. However, this effect seems not to be associated with NF-κB activity, as no significant changes were observed in its activation or in the expression of the genes that it regulates. The results of the present study demonstrate that curcumin may be used as an adjuvant agent for chemotherapy in patients with Ph+ ALL.
    Language English
    Publishing date 2019-04-02
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 2573196-8
    ISSN 1792-1082 ; 1792-1074
    ISSN (online) 1792-1082
    ISSN 1792-1074
    DOI 10.3892/ol.2019.10204
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Estimating mortality and disability in Peru before the COVID-19 pandemic: a systematic analysis from the Global Burden of the Disease Study 2019.

    Rios-Blancas, Maria Jesus / Pando-Robles, Victoria / Razo, Christian / Carcamo, Cesar P / Mendoza, Walter / Pacheco-Barrios, Kevin / Miranda, J Jaime / Lansingh, Van Charles / Demie, Takele Gezahegn / Saha, Manika / Okonji, Osaretin Christabel / Yigit, Arzu / Cahuana-Hurtado, Lucero / Chacón-Uscamaita, Pamela R / Bernabe, Eduardo / Culquichicon, Carlos / Chirinos-Caceres, Jesus Lorenzo / Cárdenas, Rosario / Alcalde-Rabanal, Jacqueline Elizabeth /
    Barrera, Francisco J / Quintanilla, Beatriz Paulina Ayala / Shorofi, Seyed Afshin / Wickramasinghe, Nuwan Darshana / Ferreira, Nuno / Almidani, Louay / Gupta, Vivek Kumar / Karimi, Hanie / Alayu, Daniel Shewaye / Benziger, Catherine P / Fukumoto, Takeshi / Mostafavi, Ebrahim / Redwan, Elrashdy Moustafa Mohamed / Gebrehiwot, Mesfin / Khatab, Khaled / Koyanagi, Ai / Krapp, Fiorella / Lee, Seung / Noori, Maryam / Qattea, Ibrahim / Rosenthal, Victor Daniel / Sakshaug, Joseph W / Wagaye, Birhanu / Zare, Iman / Ortega-Altamirano, Doris V / Murillo-Zamora, Efrén / Vervoort, Dominique / Silva, Diego Augusto Santos / Oulhaj, Abderrahim / Herrera-Serna, Brenda Yuliana / Mehra, Rahul / Amir-Behghadami, Mehrdad / Adib, Nasrin / Cortés, Sandra / Dang, Anh Kim / Nguyen, Binh Thanh / Mokdad, Ali H / Hay, Simon I / Murray, Christopher J L / Lozano, Rafael / García, Patricia J

    Frontiers in public health

    2023  Volume 11, Page(s) 1189861

    Abstract: Background: Estimating and analyzing trends and patterns of health loss are essential to promote efficient resource allocation and improve Peru's healthcare system performance.: Methods: Using estimates from the Global Burden of Disease (GBD), ... ...

    Abstract Background: Estimating and analyzing trends and patterns of health loss are essential to promote efficient resource allocation and improve Peru's healthcare system performance.
    Methods: Using estimates from the Global Burden of Disease (GBD), Injuries, and Risk Factors Study (2019), we assessed mortality and disability in Peru from 1990 to 2019. We report demographic and epidemiologic trends in terms of population, life expectancy at birth (LE), mortality, incidence, prevalence, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) caused by the major diseases and risk factors in Peru. Finally, we compared Peru with 16 countries in the Latin American (LA) region.
    Results: The Peruvian population reached 33.9 million inhabitants (49.9% women) in 2019. From 1990 to 2019, LE at birth increased from 69.2 (95% uncertainty interval 67.8-70.3) to 80.3 (77.2-83.2) years. This increase was driven by the decline in under-5 mortality (-80.7%) and mortality from infectious diseases in older age groups (+60 years old). The number of DALYs in 1990 was 9.2 million (8.5-10.1) and reached 7.5 million (6.1-9.0) in 2019. The proportion of DALYs due to non-communicable diseases (NCDs) increased from 38.2% in 1990 to 67.9% in 2019. The all-ages and age-standardized DALYs rates and YLLs rates decreased, but YLDs rates remained constant. In 2019, the leading causes of DALYs were neonatal disorders, lower respiratory infections (LRIs), ischemic heart disease, road injuries, and low back pain. The leading risk factors associated with DALYs in 2019 were undernutrition, high body mass index, high fasting plasma glucose, and air pollution. Before the COVID-19 pandemic, Peru experienced one of the highest LRIs-DALYs rates in the LA region.
    Conclusion: In the last three decades, Peru experienced significant improvements in LE and child survival and an increase in the burden of NCDs and associated disability. The Peruvian healthcare system must be redesigned to respond to this epidemiological transition. The new design should aim to reduce premature deaths and maintain healthy longevity, focusing on effective coverage and treatment of NCDs and reducing and managing the related disability.
    MeSH term(s) Aged ; Female ; Humans ; Infant, Newborn ; Male ; Middle Aged ; COVID-19/epidemiology ; Life Expectancy ; Noncommunicable Diseases ; Pandemics ; Peru/epidemiology ; Quality-Adjusted Life Years ; Respiratory Tract Infections ; Infant ; Child, Preschool
    Language English
    Publishing date 2023-06-22
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2711781-9
    ISSN 2296-2565 ; 2296-2565
    ISSN (online) 2296-2565
    ISSN 2296-2565
    DOI 10.3389/fpubh.2023.1189861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The effects of time and dose of pregnant mare serum gonadotropin (PMSG) on reproductive efficiency in hair sheep ewes.

    Quintero-Elisea, Juan A / Macías-Cruz, Ulises / Álvarez-Valenzuela, Francisco D / Correa-Calderón, Abelardo / González-Reyna, Arnoldo / Lucero-Magaña, Froylan A / Soto-Navarro, Sergio A / Avendaño-Reyes, Leonel

    Tropical animal health and production

    2011  Volume 43, Issue 8, Page(s) 1567–1573

    Abstract: The aim of this study was to evaluate the effects of dose and application time of pregnant mare serum gonadotropin (PMSG) on reproductive performance of hair sheep ewes synchronized with fluorogesterone acetate (FGA) under tropical conditions of ... ...

    Abstract The aim of this study was to evaluate the effects of dose and application time of pregnant mare serum gonadotropin (PMSG) on reproductive performance of hair sheep ewes synchronized with fluorogesterone acetate (FGA) under tropical conditions of Northeastern Mexico. Ninety-nine hair ewes (63 Blackbelly and 36 Pelibuey) were treated with intravaginal sponges during 10 days. After insertion of FGA sponges, ewes were divided into four groups, and PMSG was injected intramuscularly at doses of 100, 200, and 400 IU. Relative to FGA sponge removal, PMSG was administrated at -48 h, -24 h, and at sponge removal. PMSG was not administered to the control group. Control ewes had similar (P > 0.05) lambing rate, fertility, and fecundity than those treated with 100 IU of PMSG, but lower (P < 0.05) percentages to these variables than those treated with 200 and 400 IU of PMSG. Time to estrus decreased linearly, and ovulation rate increased quadratically as PMSG dose increased (0 to 400 IU). Administration of PMSG before sponge removal increased (P < 0.01) response to estrus and decreased (P < 0.01) interval to estrus compared with control. Ovulation rate, lambing rate, fertility, and fecundity were not affected (P > 0.05) by administration time of PMSG. Both dose and time of PMSG application did not affect (P > 0.05) pregnancy rate, percentage of single and multiple lambing, and prolificacy. In conclusion, results show that the dose of 400 IU of PMSG administered before sponge withdrawal in an estrus synchronization protocol improved reproductive efficiency of hair sheep ewes.
    MeSH term(s) Administration, Intravaginal ; Animals ; Estrus ; Estrus Synchronization ; Female ; Fertility ; Flurogestone Acetate/administration & dosage ; Flurogestone Acetate/pharmacology ; Gonadotropins, Equine/administration & dosage ; Gonadotropins, Equine/pharmacology ; Horses ; Mexico ; Ovulation ; Pregnancy ; Reproduction ; Seasons ; Sheep, Domestic/physiology ; Time Factors
    Chemical Substances Gonadotropins, Equine ; Flurogestone Acetate (X60881643X)
    Language English
    Publishing date 2011-04-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603363-5
    ISSN 1573-7438 ; 0049-4747
    ISSN (online) 1573-7438
    ISSN 0049-4747
    DOI 10.1007/s11250-011-9843-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Buffel grass (Cenchrus ciliaria L.) substitution for orange pulp on intake, digestibility, and performance of hairsheep lambs.

    Macías-Cruz, Ulises / Quintero-Elisea, Juan A / Avendaño-Reyes, Leonel / Correa-Calderón, Abelardo / Alvarez-Valenzuela, Francisco D / Soto-Navarro, S A / Lucero-Magaña, F A / González-Reyna, Arnoldo

    Tropical animal health and production

    2009  Volume 42, Issue 2, Page(s) 223–232

    Abstract: Twenty Dorper x Pelibuey male lambs were used to evaluate the effect of substitution of forage with fresh orange pulp (FOP) in diets for fattening lambs on productive behavior, nutrient intake, apparent digestibility coefficient, and feeding costs. Lambs ...

    Abstract Twenty Dorper x Pelibuey male lambs were used to evaluate the effect of substitution of forage with fresh orange pulp (FOP) in diets for fattening lambs on productive behavior, nutrient intake, apparent digestibility coefficient, and feeding costs. Lambs were divided into five groups (n = 4) and then housed in individual pens during 70 d. Treatments consisted of five levels of FOP (0, 25, 50, 75 and 100%) which substituted buffel grass hay on the base diet (40:60%, forage:concentrate). Additionally, changes in chemical composition of FOP stored in stack during 8 d were evaluated (from the day 1 until day 8). Daily feed intake expressed as kg/day and % live weight, lamb growth rate, feeding cost of each lamb per day and per fattening period, hemicellulose intake, and DM, OM, CP, NDF and hemicellulose digestibility showed a quadratic effect (P < 0.05), while DM, OM and CP intake presented a cubic effect (P < 0.05) with the increasing level of FOP. The maximum estimated value for those variables was observed at 75% of hay replacement with FOP. With respect to changes in chemical composition of pulp stored, DM content increased (P = 0.0011) from 210 to 310 g/kg FOP and OM, fiber fraction, and ash content were constant (P > 0.05) among storage days. Therefore, replacing around 75% of buffel grass hay with FOP in diets for fattening lambs resulted in the best growth rate and more efficient diet utilization. Fresh orange pulp stored in a stack did not change its chemical composition, and did not affect its utilization as a sheep feedstuff.
    MeSH term(s) Animal Feed ; Animals ; Body Weight/physiology ; Citrus sinensis/chemistry ; Citrus sinensis/metabolism ; Eating/physiology ; Feces/chemistry ; Male ; Sheep/growth & development ; Sheep/metabolism ; Sheep/physiology
    Language English
    Publishing date 2009-08-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 603363-5
    ISSN 1573-7438 ; 0049-4747
    ISSN (online) 1573-7438
    ISSN 0049-4747
    DOI 10.1007/s11250-009-9410-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

    Axfors, Cathrine / Janiaud, Perrine / Schmitt, Andreas M / Van't Hooft, Janneke / Smith, Emily R / Haber, Noah A / Abayomi, Akin / Abduljalil, Manal / Abdulrahman, Abdulkarim / Acosta-Ampudia, Yeny / Aguilar-Guisado, Manuela / Al-Beidh, Farah / Alejandria, Marissa M / Alfonso, Rachelle N / Ali, Mohammad / AlQahtani, Manaf / AlZamrooni, Alaa / Anaya, Juan-Manuel / Ang, Mark Angelo C /
    Aomar, Ismael F / Argumanis, Luis E / Averyanov, Alexander / Baklaushev, Vladimir P / Balionis, Olga / Benfield, Thomas / Berry, Scott / Birocco, Nadia / Bonifacio, Lynn B / Bowen, Asha C / Bown, Abbie / Cabello-Gutierrez, Carlos / Camacho, Bernardo / Camacho-Ortiz, Adrian / Campbell-Lee, Sally / Cao, Damon H / Cardesa, Ana / Carnate, Jose M / Castillo, German Jr J / Cavallo, Rossana / Chowdhury, Fazle R / Chowdhury, Forhad U H / Ciccone, Giovannino / Cingolani, Antonella / Climacosa, Fresthel Monica M / Compernolle, Veerle / Cortez, Carlo Francisco N / Costa Neto, Abel / D'Antico, Sergio / Daly, James / Danielle, Franca / Davis, Joshua S / De Rosa, Francesco Giuseppe / Denholm, Justin T / Denkinger, Claudia M / Desmecht, Daniel / Díaz-Coronado, Juan C / Díaz Ponce-Medrano, Juan A / Donneau, Anne-Françoise / Dumagay, Teresita E / Dunachie, Susanna / Dungog, Cecile C / Erinoso, Olufemi / Escasa, Ivy Mae S / Estcourt, Lise J / Evans, Amy / Evasan, Agnes L M / Fareli, Christian J / Fernandez-Sanchez, Veronica / Galassi, Claudia / Gallo, Juan E / Garcia, Patricia J / Garcia, Patricia L / Garcia, Jesus A / Garigliany, Mutien / Garza-Gonzalez, Elvira / Gauiran, Deonne Thaddeus V / Gaviria García, Paula A / Giron-Gonzalez, Jose-Antonio / Gómez-Almaguer, David / Gordon, Anthony C / Gothot, André / Grass Guaqueta, Jeser Santiago / Green, Cameron / Grimaldi, David / Hammond, Naomi E / Harvala, Heli / Heralde, Francisco M / Herrick, Jesica / Higgins, Alisa M / Hills, Thomas E / Hines, Jennifer / Holm, Karin / Hoque, Ashraful / Hoste, Eric / Ignacio, Jose M / Ivanov, Alexander V / Janssen, Maike / Jennings, Jeffrey H / Jha, Vivekanand / King, Ruby Anne N / Kjeldsen-Kragh, Jens / Klenerman, Paul / Kotecha, Aditya / Krapp, Fiorella / Labanca, Luciana / Laing, Emma / Landin-Olsson, Mona / Laterre, Pierre-François / Lim, Lyn-Li / Lim, Jodor / Ljungquist, Oskar / Llaca-Díaz, Jorge M / López-Robles, Concepción / López-Cárdenas, Salvador / Lopez-Plaza, Ileana / Lucero, Josephine Anne C / Lundgren, Maria / Macías, Juan / Maganito, Sandy C / Malundo, Anna Flor G / Manrique, Rubén D / Manzini, Paola M / Marcos, Miguel / Marquez, Ignacio / Martínez-Marcos, Francisco Javier / Mata, Ana M / McArthur, Colin J / McQuilten, Zoe K / McVerry, Bryan J / Menon, David K / Meyfroidt, Geert / Mirasol, Ma Angelina L / Misset, Benoît / Molton, James S / Mondragon, Alric V / Monsalve, Diana M / Moradi Choghakabodi, Parastoo / Morpeth, Susan C / Mouncey, Paul R / Moutschen, Michel / Müller-Tidow, Carsten / Murphy, Erin / Najdovski, Tome / Nichol, Alistair D / Nielsen, Henrik / Novak, Richard M / O'Sullivan, Matthew V N / Olalla, Julian / Osibogun, Akin / Osikomaiya, Bodunrin / Oyonarte, Salvador / Pardo-Oviedo, Juan M / Patel, Mahesh C / Paterson, David L / Peña-Perez, Carlos A / Perez-Calatayud, Angel A / Pérez-Alba, Eduardo / Perkina, Anastasia / Perry, Naomi / Pouladzadeh, Mandana / Poyato, Inmaculada / Price, David J / Quero, Anne Kristine H / Rahman, Md M / Rahman, Md S / Ramesh, Mayur / Ramírez-Santana, Carolina / Rasmussen, Magnus / Rees, Megan A / Rego, Eduardo / Roberts, Jason A / Roberts, David J / Rodríguez, Yhojan / Rodríguez-Baño, Jesús / Rogers, Benjamin A / Rojas, Manuel / Romero, Alberto / Rowan, Kathryn M / Saccona, Fabio / Safdarian, Mehdi / Santos, Maria Clariza M / Sasadeusz, Joe / Scozzari, Gitana / Shankar-Hari, Manu / Sharma, Gorav / Snelling, Thomas / Soto, Alonso / Tagayuna, Pedrito Y / Tang, Amy / Tatem, Geneva / Teofili, Luciana / Tong, Steven Y C / Turgeon, Alexis F / Veloso, Januario D / Venkatesh, Balasubramanian / Ventura-Enriquez, Yanet / Webb, Steve A / Wiese, Lothar / Wikén, Christian / Wood, Erica M / Yusubalieva, Gaukhar M / Zacharowski, Kai / Zarychanski, Ryan / Khanna, Nina / Moher, David / Goodman, Steven N / Ioannidis, John P A / Hemkens, Lars G

    BMC infectious diseases

    2021  Volume 21, Issue 1, Page(s) 1170

    Abstract: Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the ...

    Abstract Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ).
    Methods: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence.
    Results: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I
    Conclusions: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care.
    MeSH term(s) COVID-19/therapy ; Humans ; Immunization, Passive ; Randomized Controlled Trials as Topic ; SARS-CoV-2 ; Treatment Outcome ; COVID-19 Serotherapy
    Language English
    Publishing date 2021-11-20
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 2041550-3
    ISSN 1471-2334 ; 1471-2334
    ISSN (online) 1471-2334
    ISSN 1471-2334
    DOI 10.1186/s12879-021-06829-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top